
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen is supported by PAPZIMEOS’s strong commercial momentum, with revenue rising 37% Q/Q to $72.9M in 3Q26 and cumulative revenue reaching $151.4M since its August 2025 approval, while SG&A stayed flat and cash flow turned positive in 3Q26 at $14.8M. The company also benefits from a durable first-mover position in RRP, broad adoption across academic and community centers, and seven years of orphan exclusivity through August 14, 2032, which helps offset near-term competitive noise from VOCERYQ. Beyond the lead asset, the FDA’s September 21, 2026 platform designation for AdenoVerse, plus PRGN-2009 and other pipeline programs, supports longer-term growth and additional value creation.
Bears say
Precigen is exposed to substantial fundamental risk because, aside from PAPZIMEOS, its pipeline remains in clinical development and could face enrollment delays, weaker-than-expected efficacy or safety, and regulatory setbacks if approvals or accelerated pathways are denied. Its history of losses and capital-intensive model heighten balance-sheet pressure, and management may need to raise additional capital under unfavorable terms, which could dilute shareholders and even threaten solvency. Competitive and commercial risks also remain elevated, as INO’s VOCERYQ is approved 10/30 at price parity with a 1Q27 launch, while pricing, scheduling slippage, and patent challenges could limit sales growth and profitability.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Precigen (PGEN) Forecast
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares